Wrapmanager Inc Vertex Pharmaceuticals Inc Transaction History

Wrapmanager Inc

$375 Million
Q1 2025

A detailed history of Wrapmanager Inc transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Wrapmanager Inc holds 1,843 shares of VRTX stock, worth $832,151. This represents 0.24% of its overall portfolio holdings.

Number of Shares

1,843

Previous 2,048 10.01%

Holding current value

$832,151

Previous $824,000 8.37%

% of portfolio

0.24%

Previous 0.21%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 08, 2025	SELL	$402.49 - $513.76 $82,510 - $105,320	-205 Reduced 10.01%	1,843 $893,000
Q4 2024 Feb 04, 2025	SELL	$396.64 - $516.74 $97,176 - $126,601	-245 Reduced 10.68%	2,048 $824,000
Q3 2024 Nov 07, 2024	SELL	$460.0 - $505.78 $235,520 - $258,959	-512 Reduced 18.25%	2,293 $1.07 Million
Q2 2024 Aug 08, 2024	SELL	$392.81 - $485.53 $298,535 - $369,002	-760 Reduced 21.32%	2,805 $1.31 Million
Q1 2024 May 09, 2024	SELL	$407.69 - $446.08 $211,998 - $231,961	-520 Reduced 12.73%	3,565 $1.49 Million
Q4 2023 Feb 07, 2024	SELL	$343.0 - $410.68 $116,963 - $140,041	-341 Reduced 7.7%	4,085 $1.66 Million
Q3 2023 Nov 06, 2023	SELL	$338.18 - $362.46 $97,395 - $104,388	-288 Reduced 6.11%	4,426 $1.54 Million
Q2 2023 Aug 08, 2023	SELL	$314.42 - $351.91 $130,484 - $146,042	-415 Reduced 8.09%	4,714 $1.66 Million
Q1 2023 May 08, 2023	SELL	$283.23 - $323.1 $32,854 - $37,479	-116 Reduced 2.21%	5,129 $1.62 Million
Q4 2022 Feb 06, 2023	SELL	$285.76 - $321.48 $13,716 - $15,431	-48 Reduced 0.91%	5,245 $1.52 Million
Q3 2022 Nov 14, 2022	SELL	$273.83 - $305.53 $322,845 - $360,219	-1,179 Reduced 18.22%	5,293 $1.53 Million
Q2 2022 Aug 05, 2022	SELL	$234.96 - $292.55 $186,323 - $231,992	-793 Reduced 10.92%	6,472 $1.82 Million
Q1 2022 May 10, 2022	SELL	$221.42 - $260.97 $189,756 - $223,651	-857 Reduced 10.55%	7,265 $1.9 Million
Q4 2021 Feb 07, 2022	SELL	$177.01 - $223.45 $176,301 - $222,556	-996 Reduced 10.92%	8,122 $1.78 Million
Q3 2021 Nov 10, 2021	SELL	$181.39 - $202.99 $33,375 - $37,350	-184 Reduced 1.98%	9,118 $1.65 Million
Q2 2021 Aug 04, 2021	BUY	$187.49 - $221.1 $6,749 - $7,959	36 Added 0.39%	9,302 $1.88 Million
Q1 2021 May 10, 2021	BUY	$207.02 - $241.31 $366,632 - $427,360	1,771 Added 23.63%	9,266 $1.99 Million
Q4 2020 Feb 08, 2021	BUY	$207.01 - $276.09 $199,350 - $265,874	963 Added 14.74%	7,495 $1.77 Million
Q3 2020 Nov 12, 2020	BUY	$255.65 - $303.1 $234,431 - $277,942	917 Added 16.33%	6,532 $1.78 Million
Q2 2020 Aug 11, 2020	SELL	$225.48 - $295.8 $38,782 - $50,877	-172 Reduced 2.97%	5,615 $1.63 Million
Q1 2020 May 08, 2020	SELL	$199.77 - $247.81 $155,820 - $193,291	-780 Reduced 11.88%	5,787 $1.38 Million
Q4 2019 Feb 11, 2020	SELL	$166.71 - $223.91 $71,685 - $96,281	-430 Reduced 6.15%	6,567 $1.44 Million
Q3 2019 Nov 12, 2019	SELL	$166.23 - $187.09 $37,900 - $42,656	-228 Reduced 3.16%	6,997 $1.19 Million
Q2 2019 Jul 31, 2019	BUY	$164.61 - $190.37 $16,790 - $19,417	102 Added 1.43%	7,225 $1.33 Million
Q1 2019 May 06, 2019	SELL	$163.73 - $194.7 $52,066 - $61,914	-318 Reduced 4.27%	7,123 $1.31 Million
Q4 2018 Feb 13, 2019	SELL	$151.91 - $192.21 $7,595 - $9,610	-50 Reduced 0.67%	7,441 $1.23 Million
Q3 2018 Nov 13, 2018	BUY	$167.73 - $192.74 $5,702 - $6,553	34 Added 0.46%	7,491 $1.44 Million
Q2 2018 Aug 03, 2018	SELL	$145.72 - $169.96 $71,402 - $83,280	-490 Reduced 6.17%	7,457 $1.27 Million
Q1 2018 May 03, 2018	SELL	$151.6 - $177.13 $12,886 - $15,056	-85 Reduced 1.06%	7,947 $1.3 Million
Q4 2017 Feb 02, 2018	SELL	$137.28 - $155.55 $21,415 - $24,265	-156 Reduced 1.91%	8,032 $1.2 Million
Q3 2017 Nov 03, 2017	BUY	$148.13 - $162.24 $1.21 Million - $1.33 Million	8,188	8,188 $1.25 Million

Others Institutions Holding VRTX

# of Institutions

1,833

Shares Held

233M

Call Options Held

1.38M

Put Options Held

1.08M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $116B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wrapmanager Inc, based on Form 13F filings with the SEC.

News

Stay updated on Wrapmanager Inc with notifications on news.

Account